CVS to Buy Aetna for $69 Billion in a Deal That May Reshape the Health Industry

On Sunday, the two companies emphasized their ability to transform CVSa��s 10,000 pharmacy and clinic locations into community-based sites of care that would be far less expensive for patients.

a�?We think of it as creating a new front door to health care in America,a�? CVS Healtha��s chief executive, Larry J. Merlo, said in an interview.

The merger would establish a new way of delivering care, with nurses, pharmacists and others available to counsel people about their diabetes or do the lab work necessary to diagnose a condition, Mr. Merlo said. a�?We know we can make health care more affordable and less expensive.a�?

Mark T. Bertolini, Aetnaa��s chief executive, said that by using CVSa��s locations, the company can provide people with a better way of accessing medical care.


CVS operates 10,000 pharmacy and clinic locations, which Aetna could use to provide care directly to customers.

Mario Anzuoni/Reuters

a�?Ita��s in their community. Ita��s in their home,a�? he said. He added, a�?CVS has the draw. People trust their pharmacist.a�?

It is the development of community-based clinics a�� capable of delivering care with the technology and health information available from both parties a�� that could prove to be the biggest change brought about the deal.

The hope would be that consumers would not only be able to see savings by going to a retail store to treat a sore throat but also have better oversight of a chronic illness, such as diabetes or heart disease. They could get advice on how to lose weight, or undergo tests to monitor their health.


Continue reading the main story

a�?If they can drive the adoption of the care delivery model, thata��s a big deal,a�? said Ana Gupte, a senior health care analyst for Leerink Partners.

The merger agreement came as another factor weighs on the minds of all in the health care industry: Amazon, which has been rumored to be preparing for an entry into the pharmacy business. Jeff Bezos, the Amazon chief executive, and his e-commerce juggernaut have already overturned many industries: book buying, retail shopping, groceries and Hollywood, using fierce customer loyalty and enormous reach as cudgels against incumbent players.

But CVS and Aetna have had a business partnership dating back seven years, and have steadily converged into similar visions of how the health care industry was evolving. Conversations about a deeper bond eventually crystallized into deal talks within the last two months, according to a person with direct knowledge of the discussions.

Although neither chief executive mentioned Amazon by name, both said that what they were creating was a compelling opportunity in and of itself.

Newsletter Sign Up

Continue reading the main story

a�?Chasing our competitors has never been a solution,a�? Mr. Bertolini said. He added, a�?Our competitors will do what they do.a�?

Many companies are seeking shelter in the arms of their former adversaries, with well-known medical groups like the Cleveland Clinic joining with Oscar Health, an insurer. With federal officials blocking traditional mergers a�� like the megadeal that featured Anthem and Cigna, the nationa��s largest insurers, and one involving Aetna and its rival Humana a�� companies are looking at combinations that take them beyond their traditional lines of business.

Many analysts view the combination of CVS and Aetna as a defensive move by the companies. CVS Health, which also recently signed an agreement with Anthem to help the insurer start its own internal pharmacy benefit manager, is looking to protect its business with Aetna as it fends off rivals like UnitedHealth Groupa��s OptumRx and others. Aetna, foiled in its attempt to buy Humana, is searching for new ways to expand its business.


CVS and Aetna have had a business partnership dating back seven years, and have steadily converged into similar visions of how the health care industry was evolving.

Bill Sikes/Associated Press

The merger could also fundamentally reshape the business of overseeing drug coverage for insurers, an industry that is dominated by three large players and that has increasingly come under scrutiny over the past year as public anger over high drug prices has expanded beyond the usual culprits a�� most notably the pharmaceutical industry a�� to lesser-known players like pharmacy benefit managers.

Under the terms of the deal, CVS will pay about $207 a share, based on Fridaya��s closing prices. Roughly $145 a share of that would be in cash, with the remainder in newly issued CVS stock. The deal is expected to close in the second half of next year, subject to approval by shareholders of both companies as well as regulators.


Continue reading the main story

Antitrust approval has become an interesting question in the Trump administration, which bankers and lawyers had thought would be more tolerant of consolidation than its predecessor.

A combination of a drugstore company and an insurer is considered less problematic than a merger of two players in the same business, which could reduce competition and hurt consumers. Such concerns ultimately sank Aetnaa��s efforts to buy Humana, and Anthema��s push to buy Cigna, when the Obama administration signaled its opposition to such consolidation.

CVSa��s proposed takeover of Aetna is a so-called vertical merger, combining companies in two different industries. But while such deals have traditionally met little opposition in Washington, the Justice Department has sued to block ATTa��s $85.4 billion takeover of Time Warner on the grounds that it would create too powerful of a content company.

Both CVS and Aetna played down the prospects of regulators moving to block their deal. The breakup fee for the transaction is not especially large, reflecting that belief.

Mr. Bertolini asserted that the companies would not raise prices for consumers. a�?It doesna��t make sense for us to charge people more when we want more people in the store,a�? he said.

But analysts and other merger experts warn that the deal could be blocked by federal antitrust officials who worry that it could lessen competition. One area of focus may be Medicare; both companies are significant players in offering prescription drug plans to Medicare beneficiaries.

While the companies said they want to lower costs, CVS also makes money on rebates from drug makers and on filling prescriptions through its pharmacies.

David A. Balto, an antitrust lawyer who has been sharply critical of combinations among insurers and pharmacy benefit managers, said that he was wary of having retailers in charge of peoplea��s health. He argued that doctors may be in a better position to treat illness than retail executives.

a�?Who do you want to run the health care system?a�? he said.

Follow Michael J. de la Merced and Reed Abelson on Twitter: @m_delamerced and @reedabelson.

Katie Thomas contributed reporting.

Continue reading the main story